Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Crinetics Pharmaceuticals Inc (CRNX)
Crinetics Pharmaceuticals Inc (CRNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Crinetics Pharmaceuticals Inc 10222 Barnes Canyon Road Building #2 San Diego CA 92121 USA

www.crinetics.com P: 858-450-6464

Description:

Crinetics Pharmaceuticals Inc is a clinical stage pharmaceutical company. It focuses on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's product pipeline consists of CRN00808 for the treatment of Acromegaly, CRN02481 for the treatment of Hyperinsulinemias and CRN01941 for the treatment of Neuroendocrine Tumors which are in clinical stage. Crinetics Pharmaceuticals Inc is based in San Diego, United States.

Key Statistics

Overview:

Market Capitalization, $K 2,236,431
Enterprise Value, $K 2,203,761
Shares Outstanding, K 66,799
Annual Sales, $ 4,740 K
Annual Net Income, $ -163,920 K
Last Quarter Sales, $ 350 K
Last Quarter Net Income, $ -57,460 K
EBIT, $ -207,520 K
EBITDA, $ -206,500 K
60-Month Beta 0.55
% of Insider Shareholders 7.00%
% of Institutional Shareholders 98.51%
Float, K 62,123
% Float 93.00%
Short Volume Ratio 0.48

Growth:

1-Year Return 89.14%
3-Year Return 156.55%
5-Year Return -0.30%
5-Year Revenue Growth 131.22%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.01 on 11/07/23
Next Earnings Date 11/13/23
Earnings Per Share ttm -3.64
EPS Growth vs. Prev Qtr -7.45%
EPS Growth vs. Prev Year -29.49%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

CRNX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -57.04%
Return-on-Assets % -49.83%
Profit Margin % -3,458.23%
Net Margin % N/A
Debt/Equity 0.00
Price/Sales 468.59
Price/Cash Flow N/A
Price/Book 3.34
Book Value/Share 10.02
Interest Coverage -2.84
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar